- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02945449
Safety of Wharton Jelly in Erectile Dysfunction
Phase Ib: Evaluation of the Safety and as a Secondary End Point the Efficacy for Two Doses of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction
Study Overview
Status
Intervention / Treatment
Detailed Description
This study will be conducted at the Cell Therapy Center (CTC), Jordan, in which nine male patients ranging from 25-70 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests.
The patients are followed by clinical assessment, laboratory investigations as well as Doppler ultrasound.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Amman, Jordan, 11942
- Cell Therapy Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult male patients ranging from 25 to 70 years.
- History of chronic erectile dysfunction for at least six months.
- Baseline international index of erectile function (IIEF) score of < 26.
- Not interested or able to use phosphodiesterase type 5 inhibitor (PD5i) drug therapy and willing to forgo theses treatments for the first 6 month period following study treatment.
- Body Mass Index between 20-30.
- Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.
Exclusion Criteria:
- Current urinary tract or bladder infection.
- Clinical/Laboratory evidence of transmissible diseases.
- Clinically evident penile anatomical deformities(e.g., Peyronie's disease) or history of priapism.
- Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.
- Current or previous malignancy.
- Use of any non study treatment for erectile function within 4 weeks of study treatment.
- Lack of willingness to continue through 6 months after study treatment.
- Any previous penile implant or penile vascular surgery.
- Uncontrolled hypertension or hypotension(systolic blood pressure > 170 or < 90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg).
- Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.
- Bleeding or clotting disorder, use of anticoagulant therapy.
- Lab values for complete blood count (CBC), prothrombin time (PT)/ partial thromboplastin time (PTT)/ international normalized ratio (INR), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine falling outside the normal lab values.
- Systemic autoimmune disorder.
- Significant active systemic or localized infection.
- Receiving immunosuppressant medications.
- Post-radical prostatectomy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose I
Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
|
Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: 6 months
|
Patients will be assessed for any relevant adverse event resulting from the intracavernous injection of the Wharton jelly mesenchymal stem cells.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire
Time Frame: 12 months
|
Patients will be evaluated for the efficacy of the intracavernous injection of Wharton Jelly derived Mesenchymal Stem Cells by Sexual Health Inventory for Men/International Index of Erectile Function/Erection Hardness Score (SHIM/IIEF/EHS) questionnaire.
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WJ.EDUJCTC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
-
Sophia Al-AdwanCompletedErectile Dysfunction Associated With Type 2 Diabetes MellitusJordan
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
Ain Shams UniversityUnknownDiabetes Mellitus, Type 2 | Drug Interaction | Erectile Dysfunction With Diabetes Mellitus
-
Azienda USL ModenaCompletedErectile Dysfunction | Endothelial Dysfunction | Type 2 Diabetes Mellitus (T2DM)Italy
-
Leilei ZhuChinese Academy of SciencesWithdrawnCollagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With DiabetesType 2 Diabetes Mellitus | Erectile Dysfunction | Type 1 Diabetes MellitusChina
-
Chinese Academy of SciencesThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...UnknownType 2 Diabetes Mellitus | Erectile Dysfunction | Type 1 Diabetes MellitusChina
-
Guang'anmen Hospital of China Academy of Chinese...CompletedType 2 Diabetes Mellitus in Obese | Dyslipidemia Associated With Type II Diabetes MellitusChina
-
Laboratorios Silanes S.A. de C.V.RecruitingDyslipidemia Associated With Type II Diabetes MellitusMexico
-
Assiut UniversityNot yet recruitingDyslipidemia Associated With Type II Diabetes Mellitus
Clinical Trials on Wharton Jelly Mesenchymal stem cells
-
Sophia Al-AdwanCompletedErectile Dysfunction Associated With Type 2 Diabetes MellitusJordan
-
Sophia Al-AdwanJordan University of Science and Technology; An-Najah National UniversityUnknownDiabetic Nephropathies
-
Universidad de la SabanaFundación Neumologica Colombiana; Stem Medicina Regenerativa; Innocell SASAvailablePulmonary Fibrosis | Pulmonary Hypertension | Systemic Sclerosis PulmonaryColombia
-
TC Erciyes UniversityRecruitingRetinitis PigmentosaTurkey
-
Hanan JafarScientific Research Support fundUnknown
-
Instituto de Medicina RegenerativaActive, not recruitingCovid-19 | ARDS, HumanMexico
-
Hanan JafarRecruitingKnee OsteoarthrosisJordan
-
Ankara Universitesi TeknokentInternational Olympic CommitteeCompletedMagnetic Field Exposure | Methanol Poisoning | Toxic Optic Neuropathy | Stem Cell Tyrosine Kinase 1 Y842XTurkey
-
Samsung Medical CenterNot yet recruitingCharcot-Marie-Tooth Disease, Type 1
-
Polski Bank Komorek Macierzystych JSC (PBKM)National Center for Research and Development, PolandActive, not recruitingAmyotrophic Lateral SclerosisPoland